Applying Updated ADA/EASD Guidelines to a High Risk, Vulnerable Patient with T2D Who Has Not Achieved Target HA1c Levels after Metformin and an SGLT-2 Inhibitor Program Co-Chairs and Distinguished Faculty

Applying Updated ADA/EASD Guidelines to a High Risk, Vulnerable Patient with T2D Who Has Not Achieved Target HA1c Levels after Metformin and an SGLT-2 Inhibitor Program Co-Chairs and Distinguished Faculty


Published

November 14, 2018

Created by

CMEducation Resources symposium